OverviewSuggest Edit

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Our primary mission is to develop ZFP Therapeutics®. We have ongoing clinical programs to evaluate ZFP TFs and ZFNs as novel approaches to unmet medical needs where we believe we have a differential technical advantage to impact the outcome of disease by functioning at the DNA level.
TypePublic
Founded1995
HQRichmond, US
Websitesangamo.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2019)302(+66%)
Job Openings43
Revenue (FY, 2018)$84.5 M(+131%)
Share Price (Oct 2019)$8.6 (+4%)

Key People/Management at Sangamo BioSciences

Edward Lanphier

Edward Lanphier

President and CEO

Sangamo BioSciences Office Locations

Sangamo BioSciences has an office in Richmond
Richmond, US (HQ)
501 Canal Blvd
Show all (1)

Sangamo BioSciences Financials and Metrics

Sangamo BioSciences Revenue

Sangamo BioSciences's revenue was reported to be $84.45 m in FY, 2018
USD

Revenue (Q1, 2019)

8.1m

Net income (Q1, 2019)

(42.2m)

EBIT (Q1, 2019)

(43.9m)

Market capitalization (17-Oct-2019)

998.3m

Closing stock price (17-Oct-2019)

8.6

Cash (31-Mar-2019)

81.0m
Sangamo BioSciences's current market capitalization is $998.3 m.
Annual
USDFY, 2013Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

24.1m45.9m39.5m39.5m19.4m36.6m84.5m

Revenue growth, %

90%(14%)(51%)

General and administrative expense

13.8m19.2m26.3m27.2m46.7m

R&D expense

37.0m67.2m65.6m65.7m114.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

5.7m8.1m10.4m12.4m13.5m8.4m8.6m3.9m3.7m2.8m3.4m8.3m11.8m12.6m21.4m23.6m8.1m

General and administrative expense

3.2m3.6m4.0m3.7m4.7m5.0m4.6m5.4m11.1m5.0m7.3m6.0m6.4m10.1m11.3m11.0m17.1m

R&D expense

8.7m12.0m13.4m16.3m15.0m15.6m16.7m15.3m19.5m17.0m12.9m15.0m18.4m23.5m29.3m28.8m34.9m

Operating expense total

11.9m15.7m17.4m20.1m19.7m20.6m21.3m20.6m30.5m22.0m20.2m21.0m24.8m33.6m40.6m39.8m52.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

10.2m6.0m69.5m22.1m49.8m140.4m

Accounts Receivable

3.2m10.4m2.5m5.0m3.3m4.7m

Inventories

Current Assets

97.3m190.9m212.6m149.6m248.4m410.5m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(26.6m)(26.4m)(40.7m)(71.7m)(54.6m)(68.9m)

Depreciation and Amortization

569.0k549.0k988.0k997.0k1.5m2.4m

Inventories

Accounts Payable

269.0k(764.0k)(2.3m)3.2m(6.4m)
USDY, 2019

Revenue/Employee

26.7k

Financial Leverage

1.6 x
Show all financial metrics

Sangamo BioSciences Online and Social Media Presence

Embed Graph

Sangamo BioSciences Blogs

Sangamo Therapeutics Reports Second Quarter 2019 Financial Results

Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Content Import Wed, 08/07/2019 - 16:01 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results August 7, 2019 at 4:01 PM EDT This release is a backfill from a News Wire …

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 6, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City . The presentation is scheduled for Wednesday, August 14 at

Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 31, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019 .

Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases

BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 29, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller , Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels Content Import Fri, 07/05/2019 - 23:15 Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gen…

Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy

Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy Content Import Mon, 04/15/2019 - 16:04 Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy …
Show more

Sangamo BioSciences Frequently Asked Questions

  • When was Sangamo BioSciences founded?

    Sangamo BioSciences was founded in 1995.

  • Who are Sangamo BioSciences key executives?

    Sangamo BioSciences's key executives are Edward Lanphier.

  • How many employees does Sangamo BioSciences have?

    Sangamo BioSciences has 302 employees.

  • What is Sangamo BioSciences revenue?

    Latest Sangamo BioSciences annual revenue is $84.5 m.

  • What is Sangamo BioSciences revenue per employee?

    Latest Sangamo BioSciences revenue per employee is $279.6 k.

  • Who are Sangamo BioSciences competitors?

    Competitors of Sangamo BioSciences include BlueRock Therapeutics, PhaseBio Pharmaceuticals and Actinium Pharmaceuticals.

  • Where is Sangamo BioSciences headquarters?

    Sangamo BioSciences headquarters is located at 501 Canal Blvd, Richmond.

  • Where are Sangamo BioSciences offices?

    Sangamo BioSciences has an office in Richmond.

  • How many offices does Sangamo BioSciences have?

    Sangamo BioSciences has 1 office.